JP2002543186A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002543186A5 JP2002543186A5 JP2000615390A JP2000615390A JP2002543186A5 JP 2002543186 A5 JP2002543186 A5 JP 2002543186A5 JP 2000615390 A JP2000615390 A JP 2000615390A JP 2000615390 A JP2000615390 A JP 2000615390A JP 2002543186 A5 JP2002543186 A5 JP 2002543186A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- phenyl
- hydrogen
- immunodeficiency virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 34
- -1 6 -naphthyl Chemical group 0.000 description 22
- 229910052739 hydrogen Inorganic materials 0.000 description 18
- 239000001257 hydrogen Substances 0.000 description 16
- 241000725303 Human immunodeficiency virus Species 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 8
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 8
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 7
- 229960000311 ritonavir Drugs 0.000 description 7
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 7
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 6
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical group C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 6
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 5
- 229960004748 abacavir Drugs 0.000 description 5
- YQXCVAGCMNFUMQ-UHFFFAOYSA-N capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 5
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 5
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 229960000523 zalcitabine Drugs 0.000 description 5
- 229960002555 zidovudine Drugs 0.000 description 5
- 125000006163 5-membered heteroaryl group Chemical class 0.000 description 4
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 4
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- RYMCFYKJDVMSIR-RNFRBKRXSA-N apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 229960002656 didanosine Drugs 0.000 description 4
- 229960001627 lamivudine Drugs 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- HINZVVDZPLARRP-YSVIXOAZSA-N (4r,5s,6s,7r)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 HINZVVDZPLARRP-YSVIXOAZSA-N 0.000 description 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 3
- ATCRIOJPQXDFNY-ZETCQYMHSA-N 6-chloro-2-(1-furo[2,3-c]pyridin-5-yl-ethylsulfanyl)-pyrimidin-4-ylamine Chemical compound S([C@@H](C)C=1N=CC=2OC=CC=2C=1)C1=NC(N)=CC(Cl)=N1 ATCRIOJPQXDFNY-ZETCQYMHSA-N 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 3
- 229960003205 adefovir dipivoxil Drugs 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 229960001830 amprenavir Drugs 0.000 description 3
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 3
- 229960003804 efavirenz Drugs 0.000 description 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 229960000689 nevirapine Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 229960001852 saquinavir Drugs 0.000 description 3
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical group C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229960001203 stavudine Drugs 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000005982 diphenylmethyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- 125000003983 fluorenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000001624 naphthyl group Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- XUERKRUERHBPBL-UHFFFAOYSA-N 2-chloro-7-hydroxy-10,10-dimethyl-7-phenylpyrido[1,2-a]indole-6,8-dione Chemical compound O=C1N2C3=CC=C(Cl)C=C3C(C)(C)C2=CC(=O)C1(O)C1=CC=CC=C1 XUERKRUERHBPBL-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 0 C*(CC*1)C1=O Chemical compound C*(CC*1)C1=O 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 101150054451 Rtel1 gene Proteins 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- MLILORUFDVLTSP-UHFFFAOYSA-N emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- 229940072253 epivir Drugs 0.000 description 1
- KBEMFSMODRNJHE-JFWOZONXSA-N lodenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@@H]1F KBEMFSMODRNJHE-JFWOZONXSA-N 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229940087450 zerit Drugs 0.000 description 1
- 229940052255 ziagen Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30518799A | 1999-05-04 | 1999-05-04 | |
| US09/305,187 | 1999-05-04 | ||
| PCT/US2000/011633 WO2000066559A1 (en) | 1999-05-04 | 2000-05-01 | Piperidine derivatives useful as ccr5 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006152916A Division JP2006225407A (ja) | 1999-05-04 | 2006-05-31 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002543186A JP2002543186A (ja) | 2002-12-17 |
| JP2002543186A5 true JP2002543186A5 (https=) | 2006-07-20 |
| JP3894729B2 JP3894729B2 (ja) | 2007-03-22 |
Family
ID=23179704
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000615390A Expired - Fee Related JP3894729B2 (ja) | 1999-05-04 | 2000-05-01 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
| JP2006152916A Withdrawn JP2006225407A (ja) | 1999-05-04 | 2006-05-31 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
| JP2011151208A Pending JP2011219493A (ja) | 1999-05-04 | 2011-07-07 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006152916A Withdrawn JP2006225407A (ja) | 1999-05-04 | 2006-05-31 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
| JP2011151208A Pending JP2011219493A (ja) | 1999-05-04 | 2011-07-07 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
Country Status (32)
| Country | Link |
|---|---|
| EP (2) | EP1175402B1 (https=) |
| JP (3) | JP3894729B2 (https=) |
| KR (1) | KR100439357B1 (https=) |
| CN (2) | CN1524527A (https=) |
| AR (1) | AR023939A1 (https=) |
| AT (1) | ATE299866T1 (https=) |
| AU (2) | AU780983B2 (https=) |
| BR (1) | BR0010607A (https=) |
| CA (1) | CA2371587C (https=) |
| CO (1) | CO5170522A1 (https=) |
| CZ (1) | CZ301161B6 (https=) |
| DE (1) | DE60021371T2 (https=) |
| DK (1) | DK1175402T3 (https=) |
| EG (1) | EG24533A (https=) |
| ES (1) | ES2246233T3 (https=) |
| HK (1) | HK1039330B (https=) |
| HU (1) | HUP0203528A3 (https=) |
| IL (1) | IL145742A0 (https=) |
| MY (1) | MY141473A (https=) |
| NO (1) | NO322044B1 (https=) |
| NZ (1) | NZ514675A (https=) |
| PE (1) | PE20010113A1 (https=) |
| PL (1) | PL203117B1 (https=) |
| PT (1) | PT1175402E (https=) |
| RU (2) | RU2266281C2 (https=) |
| SA (1) | SA00210270B1 (https=) |
| SI (1) | SI1175402T1 (https=) |
| SK (1) | SK286968B6 (https=) |
| TR (2) | TR200402496T2 (https=) |
| TW (1) | TWI283666B (https=) |
| WO (1) | WO2000066559A1 (https=) |
| ZA (1) | ZA200108867B (https=) |
Families Citing this family (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| US20050065319A1 (en) * | 2000-12-19 | 2005-03-24 | Baroudy Bahige M. | Combination method for treating viral infections |
| AR033452A1 (es) | 2001-03-29 | 2003-12-17 | Schering Corp | Antagonistas de ccr5 utiles para el tratamiento del sida |
| GB0108876D0 (en) * | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
| ATE319703T1 (de) * | 2001-07-02 | 2006-03-15 | Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen | |
| GB0120461D0 (en) * | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| AR036366A1 (es) * | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| US6818773B2 (en) * | 2001-10-15 | 2004-11-16 | Schering Corporation | Synthesis of 4-[(Z)-4-bromophenyl)(ethoxyimino) methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbony)]-4'-methyl-1,4-′bipiperidine |
| AR036882A1 (es) * | 2001-10-15 | 2004-10-13 | Schering Corp | Sintesis de (4-bromofenil)(4-piperidil)metanona-(z)-o-etiloxima y sales |
| CA2467555A1 (en) * | 2001-11-29 | 2003-08-14 | Schering Corporation | Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl)-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-me thyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections |
| EP2311818B1 (en) | 2002-02-28 | 2013-01-16 | Novartis AG | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
| SE0200843D0 (sv) * | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| US6992189B2 (en) | 2002-03-29 | 2006-01-31 | Schering Corporation | Synthesis of piperidine and piperazine compounds as CCR5 antagonists |
| US20050245537A1 (en) * | 2002-04-24 | 2005-11-03 | Noboru Tsuchimori | Use of compounds having ccr antagonism |
| WO2004026833A1 (ja) * | 2002-09-20 | 2004-04-01 | Takeda Pharmaceutical Company Limited | 環状アミン化合物、その製造法および用途 |
| JP2004107298A (ja) * | 2002-09-20 | 2004-04-08 | Takeda Chem Ind Ltd | ウレア化合物およびその用途 |
| GB0223223D0 (en) * | 2002-10-07 | 2002-11-13 | Novartis Ag | Organic compounds |
| US7645771B2 (en) * | 2002-12-13 | 2010-01-12 | Smithkline Beecham Corp. | CCR5 antagonists as therapeutic agents |
| PE20040769A1 (es) * | 2002-12-18 | 2004-11-06 | Schering Corp | Derivados de piperidina utiles como antagonisas ccr5 |
| RU2366655C2 (ru) | 2003-03-14 | 2009-09-10 | Оно Фармасьютикал Ко., Лтд. | Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| WO2004092169A1 (ja) | 2003-04-18 | 2004-10-28 | Ono Pharmaceutical Co., Ltd. | スピロピペリジン化合物およびその医薬用途 |
| US20070043079A1 (en) * | 2003-04-18 | 2007-02-22 | Hiromu Habashita | Heterocyclic compound containing nitrogen atom and use thereof |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| RU2006100190A (ru) * | 2003-06-13 | 2006-08-10 | Шеринг Акциенгезельшафт (De) | Производные хинолиламида в качестве антагонистов ccr-5 |
| US7161024B2 (en) | 2003-07-10 | 2007-01-09 | Schering Corporation | Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters |
| SE0302956D0 (sv) * | 2003-11-07 | 2003-11-07 | Astrazeneca Ab | Chemical compounds |
| US7498346B2 (en) * | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| RU2006132465A (ru) | 2004-02-10 | 2008-03-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Модуляторы хемокинового рецептора ccr5 |
| SE0400925D0 (sv) * | 2004-04-06 | 2004-04-06 | Astrazeneca Ab | Chemical compounds |
| EA015517B1 (ru) | 2004-04-13 | 2011-08-30 | Инсайт Корпорейшн | Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора |
| ATE382623T1 (de) | 2004-06-09 | 2008-01-15 | Hoffmann La Roche | Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln |
| US8143404B2 (en) * | 2004-09-13 | 2012-03-27 | Ono Pharmaceutical Co., Ltd | Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| CA2595574A1 (en) * | 2005-01-20 | 2006-07-27 | Pfizer Limited. | Chemical compounds |
| JP4873352B2 (ja) * | 2005-02-16 | 2012-02-08 | シェーリング コーポレイション | Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換されたピペラジン |
| EP1858887A1 (en) * | 2005-02-23 | 2007-11-28 | Schering Corporation | Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors |
| JP4822367B2 (ja) * | 2005-02-23 | 2011-11-24 | シェーリング コーポレイション | ケモカイン受容体のインヒビターとして有用なピペリジニルピペリジン誘導体 |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP1889622A4 (en) | 2005-05-31 | 2009-12-23 | Ono Pharmaceutical Co | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF |
| US7665658B2 (en) | 2005-06-07 | 2010-02-23 | First Data Corporation | Dynamic aggregation of payment transactions |
| JP2009501793A (ja) | 2005-07-21 | 2009-01-22 | アストラゼネカ・アクチエボラーグ | 新規ピペリジン誘導体 |
| CN101291905A (zh) | 2005-10-19 | 2008-10-22 | 弗·哈夫曼-拉罗切有限公司 | 苯乙酰胺nnrt抑制剂 |
| WO2007045477A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Human antibodies against il-13 and therapeutic uses |
| EP2657235A1 (en) | 2005-10-28 | 2013-10-30 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| GB0525671D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CA2644368A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| EP2059515A2 (en) * | 2006-04-12 | 2009-05-20 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
| PT2322525E (pt) | 2006-04-21 | 2013-12-26 | Novartis Ag | Derivados de purina para utilização como agonistas do recetor de adenosina a2a |
| WO2007132846A1 (ja) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
| JP5245827B2 (ja) | 2006-07-31 | 2013-07-24 | 小野薬品工業株式会社 | スピロ結合した環状基を含有する化合物およびその用途 |
| RU2451676C2 (ru) | 2006-08-16 | 2012-05-27 | Ф.Хоффманн-Ля Рош Аг | Ненуклеозидные ингибиторы обратной транскриптазы |
| WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
| MX2009005881A (es) | 2006-12-13 | 2009-06-12 | Hoffmann La Roche | Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida. |
| RS51644B (sr) | 2007-01-10 | 2011-10-31 | Irm Llc. | Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze |
| WO2008119663A1 (en) | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CN101687851B (zh) | 2007-05-07 | 2013-02-27 | 诺瓦提斯公司 | 有机化合物 |
| CL2008003651A1 (es) | 2007-12-10 | 2009-06-19 | Novartis Ag | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. |
| CA2716838C (en) * | 2008-02-29 | 2014-01-07 | Schering Corporation | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| CA2727196A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Organic compounds |
| PL2391366T3 (pl) | 2009-01-29 | 2013-04-30 | Novartis Ag | Podstawione benzimidazole do leczenia gwiaździaków |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| NZ598220A (en) | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| CA2771432A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
| US20110098311A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorported | Compositions for treatment of cystic fibrosis and other chronic diseases |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| PT2593452T (pt) | 2010-07-14 | 2017-04-24 | Novartis Ag | Compostos heterocíclicos agonistas do receptor ip |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| CA2848809A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン， エルエルシー | Ｍｔｏｒ阻害剤を使用する強化された治療レジメン |
| US9115129B2 (en) | 2012-01-13 | 2015-08-25 | Novartis Ag | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists |
| US20150005311A1 (en) | 2012-01-13 | 2015-01-01 | Novartis Ag | IP receptor agonist heterocyclic compounds |
| US20140357641A1 (en) | 2012-01-13 | 2014-12-04 | Novartis Ag | IP receptor agonist heterocyclic compounds |
| US9174985B2 (en) | 2012-01-13 | 2015-11-03 | Novartis Ag | Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists |
| UY34572A (es) | 2012-01-13 | 2013-09-02 | Novartis Ag | Compuestos heterocíclicos agonistas del receptor ip |
| WO2013105058A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| AU2013243097A1 (en) | 2012-04-03 | 2014-10-09 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
| JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート |
| CN105189500A (zh) | 2013-02-13 | 2015-12-23 | 诺华股份有限公司 | Ip受体激动剂杂环化合物 |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| KR20160098424A (ko) | 2013-12-19 | 2016-08-18 | 바이엘 파마 악티엔게젤샤프트 | 치환된 피페리디닐-테트라히드로퀴놀린 |
| US20160318866A1 (en) | 2013-12-19 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Substituted bipiperidinyl derivatives |
| CR20160276A (es) | 2013-12-19 | 2016-10-20 | Bayer Pharma AG | "piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c" |
| EP3083610A1 (de) | 2013-12-19 | 2016-10-26 | Bayer Pharma Aktiengesellschaft | Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| BR112016024484A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| CA2954862A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) * | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| AU2020290094B2 (en) | 2019-06-10 | 2024-01-18 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis |
| AU2020338971B2 (en) | 2019-08-28 | 2023-11-23 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2676054B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| ES2182104T3 (es) * | 1996-07-10 | 2003-03-01 | Schering Corp | Piperidinas 1,4-disustituidas como antagonistas muscarinicos. |
| AU6623796A (en) * | 1996-07-25 | 1998-02-20 | Terence George Mackay | Improvements in or relating to fishing |
| JP3390179B2 (ja) * | 1996-08-15 | 2003-03-24 | シェーリング コーポレイション | エーテルムスカリン様アンタゴニスト |
| CA2296314A1 (en) * | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
-
2000
- 2000-05-01 KR KR10-2001-7013862A patent/KR100439357B1/ko not_active Expired - Fee Related
- 2000-05-01 HU HU0203528A patent/HUP0203528A3/hu unknown
- 2000-05-01 EP EP00926487A patent/EP1175402B1/en not_active Expired - Lifetime
- 2000-05-01 SI SI200030719T patent/SI1175402T1/xx unknown
- 2000-05-01 DE DE60021371T patent/DE60021371T2/de not_active Expired - Lifetime
- 2000-05-01 IL IL14574200A patent/IL145742A0/xx unknown
- 2000-05-01 CN CNA2004100282860A patent/CN1524527A/zh active Pending
- 2000-05-01 AT AT00926487T patent/ATE299866T1/de not_active IP Right Cessation
- 2000-05-01 WO PCT/US2000/011633 patent/WO2000066559A1/en not_active Ceased
- 2000-05-01 PT PT00926487T patent/PT1175402E/pt unknown
- 2000-05-01 CA CA002371587A patent/CA2371587C/en not_active Expired - Fee Related
- 2000-05-01 TR TR2004/02496T patent/TR200402496T2/xx unknown
- 2000-05-01 ES ES00926487T patent/ES2246233T3/es not_active Expired - Lifetime
- 2000-05-01 EP EP05010590A patent/EP1659111A3/en not_active Withdrawn
- 2000-05-01 NZ NZ514675A patent/NZ514675A/en not_active IP Right Cessation
- 2000-05-01 CZ CZ20013941A patent/CZ301161B6/cs not_active IP Right Cessation
- 2000-05-01 BR BR0010607-0A patent/BR0010607A/pt not_active Application Discontinuation
- 2000-05-01 AU AU45010/00A patent/AU780983B2/en not_active Ceased
- 2000-05-01 JP JP2000615390A patent/JP3894729B2/ja not_active Expired - Fee Related
- 2000-05-01 DK DK00926487T patent/DK1175402T3/da active
- 2000-05-01 SK SK1567-2001A patent/SK286968B6/sk not_active IP Right Cessation
- 2000-05-01 RU RU2001132635/04A patent/RU2266281C2/ru not_active IP Right Cessation
- 2000-05-01 PL PL351412A patent/PL203117B1/pl not_active IP Right Cessation
- 2000-05-01 TR TR2001/03213T patent/TR200103213T2/xx unknown
- 2000-05-01 HK HK02100825.9A patent/HK1039330B/en not_active IP Right Cessation
- 2000-05-01 CN CNB008071683A patent/CN1151131C/zh not_active Expired - Fee Related
- 2000-05-02 PE PE2000000406A patent/PE20010113A1/es not_active Application Discontinuation
- 2000-05-02 TW TW089108325A patent/TWI283666B/zh active
- 2000-05-02 AR ARP000102095A patent/AR023939A1/es unknown
- 2000-05-02 EG EG20000563A patent/EG24533A/xx active
- 2000-05-02 CO CO00031252A patent/CO5170522A1/es not_active Application Discontinuation
- 2000-05-02 MY MYPI20001891A patent/MY141473A/en unknown
- 2000-08-05 SA SA00210270A patent/SA00210270B1/ar unknown
-
2001
- 2001-10-26 ZA ZA200108867A patent/ZA200108867B/xx unknown
- 2001-11-02 NO NO20015365A patent/NO322044B1/no not_active IP Right Cessation
-
2005
- 2005-05-31 AU AU2005202358A patent/AU2005202358B2/en not_active Ceased
- 2005-06-23 RU RU2005120376/15A patent/RU2005120376A/ru not_active Application Discontinuation
-
2006
- 2006-05-31 JP JP2006152916A patent/JP2006225407A/ja not_active Withdrawn
-
2011
- 2011-07-07 JP JP2011151208A patent/JP2011219493A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002543186A5 (https=) | ||
| KR100613528B1 (ko) | Ｃｃｒ5 길항제, 및 이를 포함하는 약제학적 조성물 및 키트 | |
| JP3894729B2 (ja) | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 | |
| ES2244437T3 (es) | Derivados de piperazina utiles como antagonistas de ccr5. | |
| JP2004525157A5 (https=) | ||
| AU2002255947A1 (en) | CCR5 antagonists useful for treating AIDS | |
| JP2008222722A (ja) | Ｃｃｒ５アンタゴニストとして有用なピペリジン誘導体 | |
| CA2716838A1 (en) | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same | |
| CA2442210C (en) | Aryl oxime-piperazines useful as ccr5 antagonists | |
| AU2002303168A1 (en) | Aryl oxime-piperazines useful as ccr5 antagonists | |
| HK1057363B (en) | Ccr5 antagonists useful for treating aids | |
| HK1057211B (en) | Aryl oxime-piperazines useful as ccr5 antagonists |